The expression of Major Histocompatibility Complex class II (MHC II) molecules on tumour cells has emerged as a critical determinant of antitumour immunity. Conventionally restricted to professional ...
Major histocompatibility complex class II (MHC II) molecules are central to adaptive immunity, presenting peptides derived from extracellular proteins to CD4+ T helper cells. Biosynthesis begins in ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Researchers found that T cells recognize neoself-antigens -- abnormal, unfolded host proteins presented by major histocompatibility complex II (MHC-II) lacking the invariant chain -- as non-self ...
Controlling infectious diseases—especially zoonoses—is critical for both the economy and public health. Developing safe, effective vaccines remains the most reliable strategy for disease control, but ...
Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor–Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial ...
A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results